Market Intelligence, Clinical Progress, and High-Purity Reagents for Splicing-Directed Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SF3B2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SF3B2 Recombinant Protein (WT/Mutant) High purity (>90%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. Suitable for physical binding assays (SPR/BLI). |
View SF3B2 Products |
| Gene Delivery | SF3B2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View SF3B2 Products |
| Benchmark Ab | Anti-SF3B2 Recombinant Antibody Recombinant positive control for Western Blot, IP, and IHC assays. |
View SF3B2 Products |
| Validator | SF3B2 siRNA Set Target-specific gene knockdown verification in disease models. |
View SF3B2 Products |
| Related Target A | SF3B1 Core catalytic subunit of the SF3b complex. Essential for evaluating pan-splicing vs. subunit-selective inhibitors. |
View SF3B1 Products |
| Related Target B | SF3B3 Structural scaffold subunit. Critical for mapping off-target binding within the U2 snRNP complex. |
View SF3B3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disruption of Nuclear Protein-Protein Interactions (PPI) | Full-length, sequence-verified recombinant proteins preserving native domain architecture. |
| Splicing Complex Subunit Cross-reactivity Screening | Homolog panel (SF3B1, SF3B2, SF3B3, SF3B4) strictly validated via mass spectrometry. |
| Lack of Validated Knockdown Controls | Sequence-specific siRNA pool included for target validation and phenotypic rescue assays. |
| Inconsistent Target Expression in Target Cell Lines | High-titer Lentivirus particles for robust, stable SF3B2 overexpression. |
Live SF3B2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the pre-mRNA splicing machinery has emerged as a major frontier in precision oncology. SF3B2 (Splicing Factor 3B Subunit 2) is a critical component of the heptameric SF3b complex, which associates with the U2 snRNP to select the branch point sequence during pre-mRNA splicing. Dysregulation of SF3B2 is strongly implicated in oncogenic splicing addiction, particularly in MYC-driven cancers, prostate cancer, and hepatocellular carcinoma.
While early-generation splicing modulators (such as Pladienolide B derivatives and H3B-8800) primarily targeted the SF3B1 subunit, clinical development has been hampered by systemic toxicities and narrow therapeutic windows. The focus of next-generation drug discovery is shifting toward subunit-selective modulation, PROTAC-mediated degradation of specific complex components, and disrupting critical protein-protein interactions (PPIs) within the splicing machinery. Targeting SF3B2 offers a potential avenue to selectively disrupt splicing in cancer cells that exhibit heightened dependency on specific U2 snRNP components, bypassing the pan-splicing toxicity associated with global SF3B1 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Institutes, Biotech Startups | Prostate Cancer, Hematological Malignancies | High-purity SF3B2-SF3B1 interaction assays (Requires sequence-verified recombinant proteins) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Developers | MYC-driven Solid Tumors, HCC | Ternary complex formation assays (Requires high-purity, low-endotoxin SF3B2 WT protein) |
| RNA Therapeutics (ASO/siRNA) | RNAi Therapeutics Specialists | Splicing-addicted Cancers | In vitro knockdown validation (Requires target-specific siRNA and stable cell lines via Lentivirus) |